Clifford Chance advises ICG as lead on GP-led for nuclear medicine specialist Curium Pharma
Clifford Chance advises ICG as lead on GP-led for nuclear medicine specialist Curium Pharma 17 December 2020 Clifford Chance advises ICG as lead on GP-led for nuclear medicine specialist Curium Pharma Leading international law firm Clifford Chance has advised ICG Strategic Equity, as the lead investor, in CapVest’s GP-led secondary in respect of Curium Pharma, one of the largest single-asset secondary transactions to take place in 2020. Dual-headquartered in Paris and London, with manufacturing facilities across Europe and the United States, Curium Pharma is a global vertically integrated ...
Source: cliffordchance.com